News

A significant percentage ofobese patients do not progress to full cure after antibiotictreatment is completed. Among obese patients whose infection wasnot fully cured at late follow-up, health-related quality

Under the deal, the OCTC will provide integrated research, clinical trial and core lab services, while Bryla will provide commercialization services in chemistry, manufacturing and control (CMC). Bryla

The trial is designed to evaluate the safety, pharmacokinetics (PK) and efficacy of GMI-1271 when used in combination with chemotherapy in AML patients. Initially, the company is exploring

The initiation of this Phase III trial follows a Phase II trial, which showed positive results in slowing cognitive decline with 5mg/day of azeliragon in patients with mild

After completing the meeting with the agency, the company has agreed to initiate a rolling NDA submission and will submit the non-clinical and CMC components of the NDA

The main objective of the deal will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that is planned

As part of the deal, BioNTech will provide proprietary antibodies against key immunomodulatory targets that activate the immune system against cancer, while Genmab will provide access to its

The Japanese firm will continue to distribute the seasonal influenza vaccine, Influenza HA Vaccine ‘SEIKEN’, manufactured by Denka Seiken. The Preventive Vaccination Law in Japan noted that elders

The company intends to begin a Phase II clinical trial with Resunab in adults with CF within the next 90 days. CF primarily affects the lungs and digestive